Pharma giant GlaxoSmithKline (GSK) submitted its latest treatment for type two diabetes to the US Food and Drug Administration (FDA) for regulatory approval.
The firm said albiglutide BLA, an investigational once-weekly treatment for adult patients, was not yet approved as a treatment for type two diabetes or any other indication anywhere in the world.
GSK intends to submit a regulatory application in the European Union in early 2013.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
At 1030 the company's share were down 0.65% at 1,373.5p.
MM
-
Pension vs property: which option provides the best income for your retirement?News With the cost of a comfortable retirement on the rise, future retirees need to weigh up which strategy offers the best returns. But is a pension a better bet than property?
-
The industry at the heart of global technologyThe semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
